Loading clinical trials...
Loading clinical trials...
Alzheimer's Disease as a Sociosanitary Priority: ApoE Gene Polymorphism
The general objective of this randomized and longitudinal clinical study was to estimate the frequencies of ApoE variants both in the user population of the "Messengers of Peace" Residences and the "Associations of Relatives of Alzheimer's Patients" in Castile y Leon, since, due to its geographical location at the crossroads, it has received multiple genetic contributions from both northern Europe, the Mediterranean area and northern Africa. The main questions it aims to answer are: * What are the allelic frequencies of ApoE variants in the population of individuals with Alzheimer's disease in Castile and Leon? * Is there a correlation between the ApoE4 variant and the lipid profile in the blood of individuals with Alzheimer's disease in this region?
In the context of Alzheimer disease research, it is widely recognized that the ApoE gene plays a fundamental role in the genetic predisposition of this disease. With three major alleles: ApoE2, ApoE3, and ApoE4, genetic variability in the ApoE gene has been the subject of extensive attention in previous research and its association with increased risk of Alzheimer's disease has remained consistent. Within this framework, three hypotheses are proposed focused on understanding the specific influence of ApoE on Alzheimer's disease and exploring the possible underlying mechanisms. Within this framework, three hypotheses are proposed focused on understanding the specific influence of ApoE on Alzheimer disease and exploring the possible underlying mechanisms: 1. \- Research hypotheses: The genetic variant ApoE4/4 is significantly related to a higher risk of developing Alzheimer's disease compared to individuals who do not carry this genotype. 2. \- Research hypotheses: The ApoE2/2 genetic variant is associated with a lower risk of developing Alzheimer's disease compared to other genotypes. 3. \- Research hypotheses: People who carry the ApoE4 isoform have elevated levels of total cholesterol and LDL-cholesterol.
Age
60 - 90 years
Sex
ALL
Healthy Volunteers
Yes
University of León
León, Spain
Start Date
July 6, 2022
Primary Completion Date
March 13, 2023
Completion Date
March 22, 2024
Last Updated
May 8, 2024
511
ACTUAL participants
Kit Buccal swab collection & stabilization de Canvax®
DIAGNOSTIC_TEST
Cholesterol levels according to ApoE Genotype
OTHER
Assessing cardiovascular risk factors in all participants
OTHER
Lead Sponsor
Universidad de León
Collaborators
NCT07178210
NCT04123314
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions